Do you want more traffic and exposure? Get on APNews now
MarketersMEDIA / Newsroom / GeneMedi Submitted Preprint Review About 2019 nCov and Covid 19

GeneMedi Submitted Preprint Review About 2019 nCov and Covid 19

Share This Press Release

GeneMedi has submitted preprint review of 2019 nCoV and Covid 19 for a solution against this virus.

— GeneMedi has submitted a preprint for review which is about Covid 19. It offers an insight into corona virus and potential solution which is a recombination of 2019 nCoV. After this virus’ origination in China, it spread globally rapidly. It is why this company started researching about it and has submitted a preliminary scientific paper which talks about recombination drugs that will help in curing people.

This led to researching of potential recombinant proteins that is suitable for functional ELISA (enzyme-linked immunosorbent assay) along with other immunoasssays. Though the paper is yet to be published, the organization hopes that it will aid scientists worldwide to develop a drug to fight against this virus. Also, the company stated that their primary objective is not just trying to develop a drug but also develop efficient diagnosis procedure.

The CEO of this pharmaceutical company remarked, “Our research team developed this paper on corona virus after ample researching approach. The primary idea behind the paper is to have a drug that will offer people a way to fight against this virus. After it gets published in a journal people can read about it in detail.”

If the organization’s paper becomes successful in practical, then the world will have a drug to fight SARS-CoV2 as produced drugs will have the ability to create anti-agents in human body. The company is quite hopeful for this scientific paper’s success and it is attracting attention of the world quite much due to recent situation worldwide.

GeneMedi is already producing recombinant types that might create the necessary antigens required by people in present times. From investors to scientific community, general people, etc. everyone is hopeful that their produced solution will help the people battle corona virus. However, people will have to wait for its publishing and success story.

The investors of this organization is backing the company’s ideas and researching aspect completely to come up with a solution to corona virus issue. Though, there is no official statement about when the drug will be developed or available to public, but wheels are in motion that shows it will be available in market soon.

The VP of this company mentioned, “Our chief objective behind the scientific paper and the research is to come up with a drug that will cure people from corona virus. It is affecting the lives of the people as well as the world economy. Hence, we simply want to do something to change it for the better.”

So, it looks like people might get the answer to defeating SARS2 coronavirus and getting back to their normal lives in near future. However, everything depends on the success of the scientific paper and the development that takes place after it.

About the company:
GeneMedi was found over a decade ago in 2010. It is a bio-tech organization which specializes in non-viral and viral vectors that mediate gene transfer, gene expression, gene therapy, and more. GeneMedi assists scientists in process development, svcalable production, technology transfer, etc. They are known for custom made recombinant for diagnostic ingredients and drug discovery.

Contact Info:
Name: Genemedi
Email: Send Email
Organization: GeneMedi BioTech company
Address: 2nd Floor, Building 21, No 518, Xinzhuan Road,
Phone: +86-21-50478399
Website: https://www.genemedi.net/

Source URL: https://marketersmedia.com/genemedi-submitted-preprint-review-about-2019-ncov-and-covid-19/88957454

Source: MarketersMedia

Release ID: 88957454

Subscribe and Receive exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2020 MarketersMEDIA – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).